FLOWHIJACKED
עברית
Menu

NEUROMODULATION · THE CHEMISTRY OF POSSIBILITY

The chemistry that changes
what the brain can become.

A textbook-like pathway theatre for seeing how chemical signals change learning, salience, effort, threat, sleep and plasticity—and how those systems become entangled in addiction, depression and recovery.

This is not a chemical-imbalance story. The same messenger can act differently through different receptors, cells, circuits, timescales and lived contexts. The brain is schematic—not an individual scan, diagnosis or treatment recommendation.

THE RIGHT MENTAL MODEL

Your brain is not governed by a row of chemical volume knobs. It is governed by signals that arrive in particular places, at particular times, through particular receptors—after particular histories.

Dopamine can make a cue worth pursuing without making it pleasurable. Serotonin can promote patience in one circuit and anxiety in another. Noradrenaline can sharpen attention or scatter it into hypervigilance. Glutamate can write a new memory; GABA can decide whether that memory is allowed to dominate the network.

Neuromodulation is how the brain changes the meaning of its own activity.

BEFORE THE MOLECULES

Neurotransmission carries a signal. Neuromodulation changes the conditions under which that signal matters.

The boundary is porous. Dopamine and acetylcholine can carry temporally precise signals; glutamate and GABA can act through slower metabotropic receptors; many cells release more than one messenger. The brain uses a grammar, not a set of drawers.

01

SOURCE

Who releases it?

02

PATH

Where does it travel?

03

RECEPTOR

Which receptor receives it?

04

CIRCUIT

Which cell and circuit?

05

TIMING

On what timescale?

06

HISTORY

In what state, history and context?

LIVING PATHWAY ATLAS

The Neuromodulatory Pathway Theatre

Choose a system, pathway and lens. Drag gently for depth, select an origin nucleus or target, and watch the same circuit acquire a different meaning in everyday function, addiction and depression.

OBLIQUE ANATOMICAL PLATE · SCHEMATIC PROJECTION MAP LIVE
PFCACCCTXSTRNAcVPAMYHPCHYPARCPITVTASNc

Dopamine · Mesolimbic pathwayVTA → nucleus accumbens, amygdala, hippocampal field

CONCEPTUAL PATHWAY MODEL · NOT A SCAN OR DIAGNOSTIC TOOL
Every pathway, without relying on animation

The same information remains available to screen readers, print and slower study.

01

Mesolimbic pathway

VTA → nucleus accumbens, amygdala, hippocampal field

Links learned cues and outcomes to approach, vigor and updating. Its signal says that this event, place or possibility deserves learning and action—not that it is simply pleasurable.

02

Mesocortical pathway

VTA → medial/orbitofrontal PFC and ACC

Supports value updating, working memory, effort allocation and the conversion of a future possibility into an actionable policy.

03

Nigrostriatal pathway

SNc → dorsal striatum

Supports movement, action selection, skill learning and the gradual chunking of repeated behavior into efficient routines.

04

Tuberoinfundibular pathway

Arcuate hypothalamus → median eminence / pituitary

Dopamine released into portal circulation restrains prolactin secretion—an endocrine pathway often omitted from reward-centered stories.

SIX NECESSARY CORRECTIONS

Chemical slogans sound clear. The brain is less convenient—and far more interesting.

01

Dopamine = pleasure

No. Dopamine contributes to learning, incentive salience, effort and vigor. Liking and wanting are partly separable processes.

02

Serotonin = happiness

No. Seven receptor families and broad pathways participate in flexibility, threat, patience, sleep, appetite and pain—sometimes with opposing effects.

03

One messenger = one behavior

Receptor, cell type, target, timing and network state can reverse what the same messenger does.

04

Glutamate bad, GABA good

Excitation and inhibition are prerequisites for computation. Health depends on local balance, timing and plasticity—not maximizing either one.

05

Medication replaces a missing chemical

Medicines alter transporters, receptors, arousal, sleep, learning and plasticity. Treatment response does not prove a prior deficiency.

06

Brain stimulation resets chemistry

Devices perturb electrical and network dynamics. Downstream chemistry is one layer, not the whole story.

01 · THE CENTRAL CHAPTER

DA

Dopamine is not the pleasure chemical. It is the chemistry of what demands the next step.

Dopamine helps the brain learn what predicted an important outcome, give cues motivational pull, estimate whether effort is worth investing, energize action and update future choices. A person can therefore intensely want a substance they scarcely enjoy anymore.

01

Mesolimbic pathway

VTA → nucleus accumbens, amygdala, hippocampal field

Links learned cues and outcomes to approach, vigor and updating. Its signal says that this event, place or possibility deserves learning and action—not that it is simply pleasurable.

IN ADDICTION

Cues can acquire excessive incentive pull. With repetition, wanting may outlast liking and ordinary alternatives lose motivational traction; memory, stress and glutamate carry the wider learned pattern.

IN DEPRESSION

Weak reward anticipation, reduced willingness to work and blunted learning from positive outcomes can contribute to motivational anhedonia. This is neither universal nor a single ‘dopamine deficiency.’

02

Mesocortical pathway

VTA → medial/orbitofrontal PFC and ACC

Supports value updating, working memory, effort allocation and the conversion of a future possibility into an actionable policy.

IN ADDICTION

When cue value dominates while prefrontal alternatives are less available, choice can narrow around immediate state change even when long-term knowledge remains intact.

IN DEPRESSION

Altered prefrontal–striatal coupling can make value difficult to translate into initiation, planning and sustained effort.

03

Nigrostriatal pathway

SNc → dorsal striatum

Supports movement, action selection, skill learning and the gradual chunking of repeated behavior into efficient routines.

IN ADDICTION

Dorsal-striatal recruitment helps explain the shift from flexible pursuit toward stimulus-bound habit and why behavior can continue after its declared value changes.

IN DEPRESSION

Psychomotor slowing, reduced initiation and impaired action confidence can involve these loops, alongside many non-dopaminergic processes.

04

Tuberoinfundibular pathway

Arcuate hypothalamus → median eminence / pituitary

Dopamine released into portal circulation restrains prolactin secretion—an endocrine pathway often omitted from reward-centered stories.

IN ADDICTION

Its relevance is chiefly clinical and endocrine: medications and substances can alter prolactin-related function without telling us what the person wants or feels.

IN DEPRESSION

Endocrine effects, medication history and bodily symptoms require their own assessment; they should not be folded into a reward-only explanation.

NOT A LEVEL—A PATTERN

A dopamine signal can mean different things on different timescales.

01

Phasic bursts and pauses

Across many studied dopamine populations, an unexpectedly better outcome can produce a burst; when the outcome becomes predicted, much of the response moves toward the cue; omission can produce a pause. This is a reward-prediction-error teaching signal—not a universal description of every dopamine neuron.

02

Tonic state and vigor

Slower background dynamics help set how readily a system mobilizes, how much effort seems worth paying and how quickly action begins. The useful question is never simply ‘how much dopamine?’ but where, when, through which receptors and in what state.

03

Ramps, proximity and state value

Subsecond dopamine can change as an organism approaches a valued possibility. The future begins to exert force when it feels close, credible and actionable. A drug cue can exploit that mechanism; recovery can gradually recruit it for ordinary, future-compatible goals.

RECEPTOR GRAMMAR

D1 and D2 are not simple yes/no buttons.

D1-like receptors (D1, D5) and D2-like receptors (D2, D3, D4) are GPCR families with different intracellular consequences. D2 autoreceptors act as feedback brakes. The familiar D1-direct / D2-indirect diagram is useful in dorsal striatum, but not a universal code for every accumbens cell.

HOW A CUE BECOMES A COMMAND

Dopamine in addiction, across five transitions.

This is a teaching route, not a sequence every person must follow. Different substances, histories and phases recruit the system differently.

  1. 01

    An unusually consequential state change

    Different substances reach dopamine circuitry differently. Cocaine alters transporter clearance; amphetamine changes transporter and vesicular handling; nicotine recruits nicotinic receptors; opioids and cannabinoids can change inhibitory control; alcohol acts across several transmitter systems.

  2. 02

    The predictors are learned

    People, rooms, times of day, conflict, bodily sensations and rituals acquire motivational weight. The brain does not only learn the substance; it learns the road toward the state change.

  3. 03

    The response moves toward the cue

    Craving may begin before consumption. The cue increasingly carries a command-like quality: not ‘this might be rewarding’ but ‘act now.’ Dopamine contributes to that pull while memory, arousal and glutamatergic learning carry the wider pattern.

  4. 04

    Wanting and liking separate

    Motivational pull can persist or intensify while pleasure, relief, health and declared preference all deteriorate. A person may know the route is destructive while the route remains biologically prioritized.

  5. 05

    The wider control ecology changes

    Glutamatergic plasticity, dorsal-striatal habit, prefrontal availability, dynorphin, CRF, noradrenaline, GABA adaptation, sleep and social context become central. Addiction is never explained by dopamine alone.

DOPAMINE & DEPRESSION

Anhedonia is not one process.

A person may lose anticipation, willingness to work, reward learning, pleasure during experience—or some combination. These dimensions can separate biologically and psychologically. ‘Low dopamine’ therefore does not explain the experience; we must ask which part of the value–effort–action circuit became less reachable.

BOUNDARY: Dopaminergic involvement does not imply that indiscriminately increasing dopamine is effective or safe. Region, receptor, firing pattern, diagnosis, medication history and vulnerability to mania or psychosis matter.

02 · THE COUPLED ORCHESTRA

Each system changes the question the network is able to ask.

Each chapter includes origin, pathways, receptor grammar, timing, addiction, depression and a claim boundary. This is accessible depth—not one-function cards.

5-HT
02 · Indolamine neuromodulator

Serotonin

Context, patience, flexibility and bodily regulation

Where the system begins

Dorsal raphe cells project widely to cortex, striatum, amygdala and midbrain; median raphe projections strongly engage hippocampal, septal and hypothalamic fields. Caudal raphe groups descend toward brainstem and spinal targets.

What it changes

Serotonin participates in patience, behavioral inhibition, affective bias, learning from appetitive and aversive outcomes, sleep, appetite, pain and physiological regulation. Its meaning changes with receptor, target and state.

Receptor grammar

Seven receptor families and at least fourteen subtypes create divergent effects. Most are GPCRs; 5-HT3 is a fast ion channel. 5-HT1A somatodendritic and 5-HT1B terminal autoreceptors provide feedback control.

Timing and adaptation

Raphe systems combine slow regulation of state with event-linked changes. Transporter blockade occurs quickly, while clinically meaningful adaptation may require slower receptor, plasticity and learning processes.

01

Raphe–cortical projection

Dorsal raphe → prefrontal and association cortex

Modulates patience, cognitive flexibility, affective interpretation and the balance between persistence and behavioral inhibition.

ADDICTION

Can influence impulsivity, punishment sensitivity, stress coping and the ability to wait through an urge; effects differ by substance, receptor and phase.

DEPRESSION

Affective bias and cognitive flexibility may change during treatment, but depression is not established as a simple serotonin deficiency.

02

Raphe–limbic projection

Dorsal raphe → amygdala, striatum, hypothalamus

Changes threat appraisal, appetitive learning and bodily regulation through receptor-specific actions across limbic targets.

ADDICTION

Serotonin–dopamine interactions can alter cue value and impulsive choice without forming one universal ‘anti-addiction’ direction.

DEPRESSION

Threat sensitivity, anxiety, appetite and sleep may shift in different directions across people and receptor maps.

03

Median raphe–hippocampal projection

Median raphe → hippocampus and septal field

Helps regulate contextual memory, rhythmic coordination and how past experience constrains current interpretation.

ADDICTION

Contextual cues and remembered relief can recruit seeking long after acute withdrawal; extinction learning remains context-sensitive.

DEPRESSION

Hippocampal plasticity and context processing are implicated in stress and treatment, but are not reducible to transmitter level.

THE NECESSARY CORRECTION

Serotonin is neither happiness in a molecule nor irrelevant to depression. Both slogans erase receptor diversity, circuit location and adaptation.

NE
03 · Catecholamine neuromodulator

Noradrenaline / norepinephrine

Readiness, interruption, uncertainty and neural gain

Where the system begins

The locus coeruleus in the pons is the major ascending source, joined by medullary A1/A2 groups. Projection modules reach cortex, hippocampus, amygdala, thalamus, hypothalamus, cerebellum and descending autonomic systems.

What it changes

Phasic LC responses interrupt processing for salient change; tonic activity helps set wakefulness and engagement. Moderate gain can sharpen a task, while persistent high drive may promote scanning and hypervigilance.

Receptor grammar

α1, α2 and β adrenergic receptor families have different locations and time courses. α2 autoreceptors restrain further release; cortical performance often follows a state-dependent, non-monotonic relation.

Timing and adaptation

LC neurons move between sleep-related silence, tonic wakefulness and subsecond phasic responses. Stress history can retune baseline reactivity and the coupling between CRF and noradrenergic systems.

01

LC–cortical gain pathway

Locus coeruleus → PFC, cortex, ACC

Sets readiness, signal-to-noise and reorientation when the environment violates expectation.

ADDICTION

Drug cues and withdrawal can seize attentional gain, making alternatives harder to represent under stress.

DEPRESSION

Fatigue, concentration problems or anxious hyperarousal may involve different LC states; neither global ‘low’ nor ‘high’ explains them.

02

LC–limbic stress pathway

Locus coeruleus → amygdala, hippocampus, hypothalamus

Coordinates memory for arousing events with threat appraisal and bodily mobilization.

ADDICTION

Reciprocal CRF–LC recruitment contributes to stress-induced seeking and the autonomic distress of withdrawal, especially with opioids.

DEPRESSION

Anxious arousal, disturbed sleep and negative memory bias may be amplified when this loop becomes persistently available.

03

Thalamic–cerebellar projection field

Locus coeruleus → thalamus and cerebellum

Extends arousal control into sensory gating, timing and adaptive coordination beyond the cortex.

ADDICTION

Sleep loss and persistent arousal can destabilize timing, interoception and the capacity to pause before a learned action.

DEPRESSION

Bodily slowing, agitation and sleep disturbance implicate distributed networks rather than one mood center.

THE NECESSARY CORRECTION

More noradrenaline is not simply more focus. The same arousal system can sharpen selection or dissolve it into hypervigilance.

GLU
04 · Principal excitatory transmitter

Glutamate

Fast excitation, coincidence detection and the writing of plasticity

Where the system begins

Glutamate is distributed throughout cortical, hippocampal, thalamic and subcortical projection neurons; it does not arise from one compact source nucleus. Astrocytes clear it and participate in the glutamate–glutamine cycle.

What it changes

AMPA receptors carry much fast excitation; NMDA receptors detect coincidence and help modify synapses; metabotropic receptors regulate slower network conditions. Together they allow experience to alter future responsiveness.

Receptor grammar

AMPA, NMDA and kainate ionotropic receptors operate beside mGluR groups. Function depends on subunit, synaptic location, voltage, co-agonists, glial clearance and inhibitory context.

Timing and adaptation

Fast postsynaptic currents unfold in milliseconds; plasticity can change a synapse for hours, months or longer. Acute and chronic drug effects therefore cannot be read from the same timescale.

01

Corticostriatal pathway

PFC / cortex → nucleus accumbens and dorsal striatum

Converts goals, rules and expected outcomes into action selection while updating synapses from experience.

ADDICTION

Repeated exposure can change AMPA/NMDA plasticity and glutamate homeostasis, allowing cues or contexts to trigger seeking after long abstinence.

DEPRESSION

Stress-related changes in prefrontal synapses and plasticity may impair flexible control; rapid antidepressant mechanisms cannot be reduced to simply ‘less glutamate.’

02

Hippocampal–prefrontal context route

Hippocampal field → PFC / ACC

Carries contextual memory into present planning so the same cue can mean something different in a different place or time.

ADDICTION

Context-specific relapse and renewal show why extinction does not erase the old memory; new learning must become retrievable where it matters.

DEPRESSION

Rumination and overgeneralized negative memory can constrain what futures the prefrontal system can construct.

03

Amygdala–accumbens cue route

Amygdala → nucleus accumbens / ventral pallidum

Lets learned emotional significance bias which option wins competition for action.

ADDICTION

A small sensory cue can reactivate a large learned state when synaptic weights and stress conditions favor the old route.

DEPRESSION

Negative salience can dominate selection even while positive outcomes remain intellectually recognized.

THE NECESSARY CORRECTION

Glutamate is not ‘bad excitation.’ Without precisely gated excitation there is no perception, memory, planning or relearning.

GABA
05 · Principal inhibitory transmitter

GABA

Inhibition, timing, competition and protection from runaway activity

Where the system begins

GABA is released by cortical interneurons, striatal projection neurons, pallidal neurons and local inhibitory cells throughout the brain. It is a distributed grammar of gating rather than one calming tract.

What it changes

Fast GABA-A currents, slower GABA-B signaling and extrasynaptic tonic inhibition regulate when neurons fire, which ensemble wins and whether excitation remains informative rather than unstable.

Receptor grammar

GABA-A receptors are ligand-gated chloride channels with many subunit combinations; GABA-B receptors are slower GPCRs. Drug action depends on receptor subtype, location and existing network state.

Timing and adaptation

Synaptic inhibition shapes millisecond timing; tonic conductance sets longer background gain. Chronic alcohol or sedative exposure can induce adaptations whose withdrawal unfolds on a very different, potentially dangerous timescale.

01

VTA inhibitory gate

Local / pallidal GABA → VTA dopamine cells

Inhibitory cells decide when midbrain dopamine populations can burst and which inputs gain influence.

ADDICTION

Disinhibition is one route by which opioids and other drugs alter reward circuitry; the exact mechanism differs across substances.

DEPRESSION

Local inhibitory microcircuits can alter reward and cortical signal-to-noise without implying a global GABA shortage.

02

Striatal–pallidal selection loop

Striatum → pallidal output → thalamocortical loop

Gates competing actions by inhibiting inhibitors—a architecture in which timing and cell identity matter more than the word ‘calming.’

ADDICTION

Repeated behavior can become efficiently released by familiar cues as dorsal-striatal habits consolidate.

DEPRESSION

Psychomotor and decisional symptoms can emerge when action-selection thresholds become difficult to cross.

03

Cortical interneuron field

Local GABA interneurons ↔ cortical pyramidal ensembles

Coordinates rhythms and preserves selectivity so one representation can become clear without the whole network activating.

ADDICTION

Stress, sleep loss and substance adaptation can degrade cortical control partly by changing local excitation–inhibition timing.

DEPRESSION

Cell-specific E/I changes, including somatostatin interneuron findings, are more plausible than a single global inhibitory deficit.

THE NECESSARY CORRECTION

GABA is not universally ‘good calm.’ Too little, too much, or inhibition in the wrong cells can each degrade computation. Alcohol and sedative withdrawal may require urgent medical care.

μ / κ
06 · Endogenous peptide system

Endogenous opioids

Pleasure, relief, pain and the dark side of stress

Where the system begins

β-endorphin, enkephalins, dynorphins and nociceptin are produced in distributed hypothalamic, striatal, brainstem and local circuits.

What it changes

μ signaling participates in analgesia, reward and relief; δ signaling contributes to affect and plasticity; dynorphin–κ signaling can support dysphoria, aversion and stress-related anti-reward.

Receptor grammar

μ, δ, κ and NOP are GPCR families whose effect depends on peptide, cell and circuit. Exogenous opioid drugs produce pharmacokinetics far outside the normal spatial and temporal pattern.

Timing and adaptation

Peptide release often follows intense or sustained activity and can reshape networks for seconds to minutes; dependence and stress adaptation unfold over much longer periods.

01

μ-opioid reward–relief field

VTA / accumbens / ventral pallidum / brainstem

Coordinates analgesia, relief and hedonic amplification across small circuit-specific zones.

ADDICTION

Exogenous μ agonists can disinhibit VTA dopamine and powerfully reinforce relief while dependence recruits autonomic and stress circuitry.

DEPRESSION

Reduced pleasure and social reward may involve opioid function, but no single opioid-level account explains depression.

02

Dynorphin–κ stress field

Extended limbic / hypothalamic circuits → dopamine and stress nodes

Signals aversive load and can reduce reward responsiveness during sustained stress.

ADDICTION

Recruitment during withdrawal can make substance use negatively reinforcing: the drug is taken to escape the state it helped create.

DEPRESSION

Dysphoria and stress sensitivity make this a candidate mechanism in some depressive states, not a universal cause.

THE NECESSARY CORRECTION

Pleasure, relief and wanting are separable. Opioid signaling helps explain relief and liking, but opioid addiction also recruits dopamine, LC, glutamate and extended-amygdala stress systems.

eCB
07 · Activity-dependent lipid signals

Endocannabinoids

On-demand local feedback for stress, memory and release probability

Where the system begins

Anandamide and 2-AG are synthesized on demand in postsynaptic cells rather than stored like conventional vesicular transmitters.

What it changes

They commonly travel backward to presynaptic CB1 receptors and reduce glutamate or GABA release, regulating stress buffering, fear extinction, appetite, pain, memory and reward.

Receptor grammar

CB1 is abundant in brain terminals; CB2 is more prominent in immune-related signaling but also appears in neural contexts. Enzymes that synthesize and degrade each ligand create local timing.

Timing and adaptation

Signals are triggered by recent cellular activity and often act locally for seconds to minutes. THC is not equivalent to this precisely timed retrograde feedback.

01

Retrograde local feedback

Postsynaptic cell → presynaptic CB1 terminal

Temporarily reduces incoming release according to recent postsynaptic demand.

ADDICTION

Chronic drug exposure can disrupt CB1-dependent plasticity and alter stress-triggered seeking.

DEPRESSION

Stress buffering and fear extinction may be altered in some states; findings are circuit- and exposure-dependent.

02

Endocannabinoid VTA gate

Corticolimbic inputs ↔ VTA inhibitory/excitatory terminals

Tunes the balance of excitation and inhibition reaching motivational neurons.

ADDICTION

Cannabinoids and other drugs can alter this gate, changing dopamine-linked learning without reducing the mechanism to dopamine alone.

DEPRESSION

Bidirectional effects and exposure history prevent a simple ‘more is better’ account.

THE NECESSARY CORRECTION

The endogenous cannabinoid system is not simply ‘the brain’s cannabis.’ Exogenous THC has a different dose, spread and persistence.

ACh
08 · Cholinergic transmitter and modulator

Acetylcholine

Attention, cue detection, memory selection and action switching

Where the system begins

Basal forebrain and medial septal systems project to cortex, amygdala and hippocampus; PPT/LDT cells reach thalamus, basal ganglia and VTA; striatal cholinergic interneurons act locally.

What it changes

Acetylcholine marks information that deserves processing, supports cortical attention and hippocampal encoding, and interacts with dopamine during action learning.

Receptor grammar

Nicotinic receptors are fast ion channels; muscarinic M1–M5 receptors are slower GPCRs. Receptor activation and desensitization can create different phases of effect.

Timing and adaptation

Brief transients can accompany cue detection, while slower tone alters cortical state. Nicotine repeatedly activates and desensitizes selected receptor populations.

01

Basal forebrain–cortical pathway

Basal forebrain → cortex / amygdala

Sharpens detection and stabilizes task-relevant representations.

ADDICTION

Drug cues can become attention magnets; cholinergic signaling helps explain why learned sensory details capture processing.

DEPRESSION

Attention, memory and affect may shift bidirectionally; this is not another one-transmitter deficiency.

02

PPT/LDT–VTA pathway

PPT / LDT → VTA, thalamus and basal ganglia

Links arousal, sensory state and action systems with midbrain learning.

ADDICTION

Nicotine directly recruits nicotinic receptors in and around VTA, changing excitation, inhibition and dopamine release.

DEPRESSION

Arousal and cognitive symptoms may involve these interactions, but evidence is heterogeneous.

THE NECESSARY CORRECTION

Acetylcholine is not a single ‘memory chemical.’ It selects, gates and coordinates information across several source systems.

OX
09 · Hypothalamic neuropeptide system

Orexin / hypocretin

The bridge between need, wakefulness and sustained pursuit

Where the system begins

A small population in lateral, perifornical and dorsomedial hypothalamus projects widely to LC, raphe, basal forebrain, VTA and autonomic targets.

What it changes

Orexin stabilizes wakefulness and mobilizes pursuit when a biologically important goal requires sustained effort. Loss of orexin neurons causes narcolepsy.

Receptor grammar

OX1 and OX2 are GPCRs with different distributions; their effects depend on arousal state, target and metabolic context.

Timing and adaptation

Activity tracks wakeful need and motivational state across seconds to hours, linking circadian, metabolic and learned information.

01

Hypothalamic arousal fan

Lateral hypothalamus → LC, raphe, basal forebrain

Stabilizes wakefulness and coordinates multiple arousal systems around current need.

ADDICTION

Stress and drug-predictive cues can recruit orexin, sustaining seeking and reinstatement rather than pleasure itself.

DEPRESSION

Findings vary with insomnia, hypersomnia, agitation, fatigue and subtype; one direction cannot fit all depressive states.

02

Orexin–VTA pursuit route

Lateral hypothalamus → VTA / accumbens

Helps energize goal pursuit when the opportunity is salient and effortful.

ADDICTION

Can promote cue-triggered seeking and stress-related reinstatement, making it a bridge between arousal and motivational capture.

DEPRESSION

Reduced or dysregulated mobilization may contribute to fatigue in some people, while excess arousal may dominate in others.

THE NECESSARY CORRECTION

Orexin is not pleasure. It is especially important when pursuit must be sustained despite effort, stress or delay.

THE SUPPORTING CHORUS

These are not background actors.

Wakefulness, sleep pressure, stress response, relationship and plasticity alter what every major transmitter system can do.

01

Histamine

Tuberomammillary hypothalamic neurons project broadly to sustain wakefulness, attention and metabolic readiness. H1/H2 carry postsynaptic effects; H3 provides important presynaptic feedback. Its clearest relevance here is sleep, cognition and medication side effects—not a proven primary cause of addiction or depression.

02

Adenosine

A cellular-use signal and sleep-pressure regulator. A1 broadly restrains excitability; striatal A2A interacts strongly with D2-related circuitry. Caffeine promotes wakefulness largely by blocking adenosine receptors.

03

CRF, dynorphin and NPY

CRF mobilizes endocrine and extended-amygdala stress responses; dynorphin–κ can deepen dysphoria; NPY often counterbalances stress. Their competition helps explain why withdrawal can turn use from reward-seeking into relief-seeking.

04

Oxytocin and vasopressin

Projection-defined hypothalamic systems shape social salience, attachment, threat and bodily regulation. Oxytocin is not a universal trust hormone; context and relationship determine whether social information feels safe, important or threatening.

05

BDNF and growth signaling

BDNF is not a classical neurotransmitter. It helps stabilize activity-dependent synaptic and structural change, making it relevant to chronic stress, treatment, addiction learning and the slow consolidation of recovery.

03 · THE ADDICTION LENS

Addiction is not a pleasure system stuck ‘on.’

It is a learning, motivation, stress, habit and control ecology progressively organized around one unusually powerful state transition. The three-stage model helps us navigate—but it is neither fixed order nor destiny.

01

Binge / intoxication

VTA and ventral striatum assign salience and reinforcement; endogenous opioids shape relief and liking; GABA, glutamate, acetylcholine and endocannabinoids determine how each drug reaches the circuit. With repetition, dorsal-striatal habit gains influence.

02

Withdrawal / negative affect

Extended amygdala, LC and hypothalamic stress systems recruit CRF, noradrenaline and dynorphin. Ordinary rewards lose traction while distress and remembered relief gain precision. Use can become negatively reinforcing because it temporarily removes the state it helped create.

03

Preoccupation / anticipation

PFC, ACC, insula, hippocampus, amygdala and striatum combine remembered context, cue-linked dopamine, glutamatergic plans, arousal and orexin-supported pursuit. The future compresses around one immediately reachable state change.

SYSTEM STORY: A CUE APPEARS

01Amygdala and hippocampus identify relevance and context02Acetylcholine sharpens cue detection03Noradrenaline mobilizes attention and arousal04Glutamate carries the representation into PFC and accumbens05Dopamine gives the cue incentive weight06Orexin helps sustain pursuit

04 · THE DEPRESSION LENS

Depression is a family of network states—not a blood test for one transmitter.

The same diagnosis can contain anhedonia, agitation, anxiety, hypersomnia, insomnia, cognitive slowing, pain or motivational collapse in very different proportions. A circuit-and-dimension model is more faithful than a single-molecule model.

01

Anticipation and effort

VTA–accumbens–ACC loops: can a positive outcome be anticipated, and does it feel worth mobilizing for? Dopamine, glutamate and opioids contribute in different phases.

02

Pleasure during experience

Ventral pallidum, accumbens hedonic zones, OFC and insula help distinguish consummatory liking from anticipatory wanting.

03

Negative bias and rumination

Amygdala, hippocampus and medial prefrontal networks can repeatedly privilege threat, failure and self-referential material; serotonin, glutamate, GABA and noradrenaline participate without forming one imbalance.

04

Stress and anxious arousal

LC, BNST, amygdala and hypothalamic stress axes shape vigilance, bodily alarm and sleep through noradrenaline, CRF, orexin and serotonin.

05

Cognitive and psychomotor slowing

Prefrontal, cingulate, thalamocortical and basal-ganglia loops influence initiation, working memory and movement. Dopamine, noradrenaline, acetylcholine and E/I balance all matter.

06

Sleep, pain and the body

Orexin, histamine, adenosine, GABA, serotonin, noradrenaline, opioids and circadian systems couple mood to bodily state. The body is part of the disorder, not a side effect of the mind.

There is no accepted neurotransmitter test that diagnoses depression. Molecules participate in experience—but person, body, relationship, learning and world are not side effects of the molecule.

05 · TWO MEANINGS OF NEUROMODULATION

Chemistry changes parameters. Technology can perturb a network. Both meet a whole state.

Medication may change transporters, receptors, release, arousal, sleep and plasticity. Brain or nerve stimulation may change activity patterns and communication between networks. Neither proves the illness was a ‘deficiency’ of the target it influenced.

01

TMS / rTMS / iTBS

Magnetic pulses perturb cortical tissue and influence connected networks. Protocol, target, dose and diagnosis matter; a surface target is an entrance to a network, not the whole mechanism.

02

ECT

A controlled seizure is induced under anesthesia. ECT has strong evidence in several severe or urgent depressive states, while its network, plasticity and neuroendocrine effects are much broader than a single transmitter correction. Memory trade-offs require explicit clinical discussion.

03

VNS

Vagus-nerve stimulation enters through brainstem pathways, including NTS-linked access to LC, raphe and forebrain networks. Implanted and noninvasive forms have different evidence and indications.

04

DBS and adaptive stimulation

Implanted electrodes can influence deep circuits with target- and timing-specific stimulation. DBS is established for selected neurological indications; psychiatric uses remain more experimental. Closed-loop systems aim to respond to measured circuit state.

05

tDCS / tACS

Weak direct or alternating currents bias excitability and oscillatory timing rather than force one region ‘on.’ Evidence varies substantially by indication, montage and protocol.

06

Focused ultrasound

Thermal, ablative and low-intensity approaches are fundamentally different. Psychiatric neuromodulation remains an emerging field whose precision of targeting must not be confused with precision of clinical meaning.

CLINICAL BOUNDARY

Regulatory status and evidence vary by jurisdiction, indication and protocol. These are clinician-delivered interventions, not self-treatment instructions. Selection depends on diagnosis, severity, risk, medical history, prior response, substance use and vulnerability to mania or psychosis.

THE FLOW HIJACKED LENS

Not maximizing a good chemical. Recovering range and navigability.

A chemical does not write behavior directly. It changes the gain, timing and plasticity of a living field already shaped by body, memory, relationships, cues, treatment and world. Recovery is therefore not a return to one ‘normal level,’ but the rebuilding of an ability to mobilize without capture, tolerate distress and let ordinary rewards become biologically meaningful again. This is a Flow Hijacked conceptual synthesis—not a separately validated scientific theory.

CONCEPTUAL TEACHING EQUATION
Effect=f(M × R × C × P × T × S × H × X)
messenger × receptor × cell × pathway × timing × state × history × context

This is not a measurable clinical formula. It is a reminder that the same molecule can produce a different result in a different circuit, time and history.

06 · THE FOUNDATION FOR WHAT COMES NEXT

This page is not the lecture series. It is the map on which the series can become dense.

Each future gate can deepen anatomy, receptors, learning mathematics, human and animal evidence, clinical translation, claim boundaries and lived experience under the Flow Hijacked lens.

  1. 01The Grammar of Neuromodulation
  2. 02Dopamine I — Anatomy of Pursuit
  3. 03Dopamine II — Prediction Error, Effort and Wanting
  4. 04Dopamine III — How Cues Become Commands
  5. 05Dopamine IV — Anhedonia, Motivation and Depression
  6. 06Serotonin — Flexibility, Patience and Affective Context
  7. 07Noradrenaline — Uncertainty and the Stress Gate
  8. 08Glutamate and GABA — How Experience Rewrites the Circuit
  9. 09Endogenous Opioids — Pleasure, Relief and Dysphoria
  10. 10Endocannabinoids — The Brain’s Local Feedback System
  11. 11Orexin, Histamine, ACh and Adenosine — Wakeful Pursuit
  12. 12CRF, NPY and the Social–Stress Field
  13. 13The Neuromodulatory Ecology of Addiction
  14. 14The Neuromodulatory Ecology of Depression
  15. 15Recovery as Recalibration — Timing, Range and Context

RESEARCH ANCHORS

A map must show its boundaries as clearly as its routes.

A curated starting library, not a complete systematic review. Many pathways combine anatomy, animal studies, human imaging, pharmacology and clinical data; causal strength is not identical across them.

01Dopamine reward prediction-error signalling

Schultz (2016) · Dialogues in Clinical Neuroscience

02Ventral tegmental area: cellular heterogeneity, connectivity and behaviour

Morales & Margolis (2017) · Nature Reviews Neuroscience

03Liking, wanting, and incentive-sensitization

Berridge & Robinson (2016) · American Psychologist

04Neurobiology of addiction: a neurocircuitry analysis

Koob & Volkow (2016) · The Lancet Psychiatry

05Drug addiction: updating actions to habits to compulsions

Everitt & Robbins (2016) · Annual Review of Psychology

06Drug-evoked synaptic plasticity in addiction

Lüscher & Malenka (2011) · Neuron

07Serotoninergic regulation of emotional and behavioural control

Cools, Roberts & Robbins (2008) · Trends in Cognitive Sciences

08An integrative theory of locus coeruleus–norepinephrine function

Aston-Jones & Cohen (2005) · Annual Review of Neuroscience

09Altered connectivity in depression: GABA and glutamate

Duman, Sanacora & Krystal (2019) · Neuron

10Depression, stress, and anhedonia

Pizzagalli (2014) · Annual Review of Clinical Psychology

11The brain reward circuitry in mood disorders

Russo & Nestler (2013) · Nature Reviews Neuroscience

12The molecular basis of drug addiction

Nestler & Lüscher (2019) · Neuron